Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate Cancer targeting using human xenograft tumors in mice

Janeen H. Trembley, Gretchen M. Unger, Vicci L. Korman, Md Joynal Abedin, Lucas P. Nacusi, Rachel I. Vogel, Joel W. Slaton, Betsy T. Kren, Khalil Ahmed

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Protected and specific delivery of nucleic acids to malignant cells remains a highly desirable approach for cancer therapy. Here we present data on the physical and chemical characteristics, mechanism of action, and pilot therapeutic efficacy of a tenfibgen (TBG)-shell nanocapsule technology for tumor-directed delivery of single stranded DNA/RNA chimeric oligomers targeting CK2αα′ to xenograft tumors in mice. The sub-50 nm size TBG nanocapsule (s50-TBG) is a slightly negatively charged, uniform particle of 15 - 20 nm size which confers protection to the nucleic acid cargo. The DNA/RNA chimeric oligomer (RNAi-CK2) functions to decrease CK2αα′ expression levels via both siRNA and antisense mechanisms. Systemic delivery of s50-TBG-RNAi-CK2 specifically targets malignant cells, including tumor cells in bone, and at low doses reduces size and CK2-related signals in orthotopic primary and metastatic xenograft prostate cancer tumors. In conclusion, the s50- TBG nanoencapsulation technology together with the chimeric oligomer targeting CK2αα′ offer significant promise for systemic treatment of prostate malignancy.

Original languageEnglish (US)
Article numbere109970
JournalPloS one
Volume9
Issue number10
DOIs
StatePublished - Oct 15 2014

Fingerprint Dive into the research topics of 'Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate Cancer targeting using human xenograft tumors in mice'. Together they form a unique fingerprint.

Cite this